David A. Siegel Arcturus Therapeutics Holdings Inc. Transaction History

Two Sigma Advisers, LP

$47 Billion
Q3 2025

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Arcturus Therapeutics Holdings Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 38,500 shares of ARCT stock, worth $279,895. This represents 0.0% of its overall portfolio holdings.

Number of Shares

38,500

Previous 48,500 20.62%

Holding current value

$279,895

Previous $630,000 12.54%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$11.39 - $22.17 $113,900 - $221,700	-10,000 Reduced 20.62%	38,500 $709,000
Q2 2025 Aug 14, 2025	BUY	$8.91 - $14.41 $432,135 - $698,885	48,500 New	48,500 $630,000
Q3 2021 Nov 15, 2021	SELL	$27.88 - $58.25 $8.93 Million - $18.7 Million	-320,343 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$25.79 - $42.11 $1.24 Million - $2.02 Million	48,000 Added 17.62%	320,343 $10.8 Million
Q1 2021 May 17, 2021	BUY	$38.75 - $86.92 $3.75 Million - $8.41 Million	96,700 Added 55.05%	272,343 $11.2 Million

Q4 2020 Feb 16, 2021	BUY	$34.61 - $123.66 $616,058 - $2.2 Million	17,800 Added 11.28%	175,643 $7.62 Million
Q3 2020 Nov 16, 2020	BUY	$37.49 - $63.19 $1.82 Million - $3.07 Million	48,600 Added 44.49%	157,843 $6.77 Million
Q2 2020 Aug 14, 2020	BUY	$12.66 - $58.27 $763,398 - $3.51 Million	60,300 Added 123.2%	109,243 $5.11 Million
Q1 2020 May 15, 2020	SELL	$9.31 - $18.26 $931 - $1,826	-100 Reduced 0.2%	48,943 $665,000
Q4 2019 Feb 14, 2020	BUY	$8.93 - $12.41 $437,953 - $608,623	49,043 New	49,043 $533,000

Others Institutions Holding ARCT

# of Institutions

173

Shares Held

26M

Call Options Held

2.32M

Put Options Held

866K

View Full List

About Arcturus Therapeutics Holdings Inc.

Ticker ARCT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,576,400
Market Cap $193M
Description
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lun...

More about ARCT

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account